Amgen Neupogen Neulasta Counterattack strategies PROMOTIONAL EFFORTS Amgen

Amgen Neupogen & Neulasta Counter-attack strategies PROMOTIONAL EFFORTS • Amgen continues to reinforce NEUPOGEN’s long track record of clinical efficacy and reliable supply to patients 1 • To translate their substantial experience with NEUPOGEN biosimilars in Europe to the US market 1 NEW ADMINISTRATION OPTIONS • Neulasta Delivery Kit, will enable Amgen to maintain greater market share following the launch of competing biosimilar products 2 • Amgen’s On-Body injector for Neulasta approved in the US (Dec’ 14)3; and launched on Mar 02’ 154 (Update: Mar 02, 2015; Amgen Press Release) IP PROTECTION • Amgen is involved with Sandoz in Biologics Price Competition and Innovation Act (BPCIA) ‘patent dance’ with the hopes of delaying the market entry of Sandoz’ biosimilar of Neupogen 5 • Amgen has demanded preliminary injunction arguing that Sandoz’s market entry will be illegal and with claims of patent infringement 6 • Sandoz has agreed that they will not launch the biosimilar in the US until April 10 or a favorable court ruling in litigation over its compliance with the biosimilar statute 7 (Update: Feb 25, 2015) 1 Source: 1. Q 4 2014 Amgen Earnings Conference Call Presentation 2. Seeking Alpha 3. Amgen @ JP Morgan Healthcare Conference 4. Amgen Press Release 5. K L Gates. com 6. Law 360. com 7. The Pink Sheet Daily [Subscription required]